New ELISA for B cell-activating factor

Clinical Chemistry

Volumn 55, Issue 10, 2009, Pages 1843-1851

  Le Pottier, Laëtitia ^a,b   Bendaoud, Boutahar ^c   Renaudineau, Yves ^a,b,c   Youinou, Pierre ^a,b,c   Pers, Jacques Olivier ^a,b,c   Daridon, Capucine ^a,b  

^a Universite de Brest   (France)

^b UNIVERSITÉ EUROPÉENNE DE BRETAGNE   (France)

^c BREST UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

B CELL ACTIVATING FACTOR; MONOCLONAL ANTIBODY; POLYCLONAL ANTIBODY; RECOMBINANT PROTEIN; RHEUMATOID FACTOR;

ANALYTIC METHOD; ANTIBODY AFFINITY; ANTIGEN DETECTION; ARTICLE; AUTOIMMUNE DISEASE; CONTROLLED STUDY; CROSS REACTION; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN GLYCOSYLATION; PROTEIN PURIFICATION; QUANTITATIVE ASSAY; RELIABILITY;

CAPRA HIRCUS;

ANIMALS; ANTIBODIES; ANTIBODIES, MONOCLONAL; B-CELL ACTIVATING FACTOR; BODY FLUIDS; ENZYME-LINKED IMMUNOSORBENT ASSAY; GLYCOSYLATION; GOATS; HUMANS; RABBITS; RECOMBINANT PROTEINS; SALIVA;

EID: 70349667180     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2009.129940     Document Type: Article

References (39)

1. Schneider P, MacKay F, Steiner V, Hofmann K, Bodmer JL, Holler N, et al. BAFF, a novel ligand of the TNF family, stimulates B cell growth. J Exp Med 1999;189:1747-1756
2. Hahne M, Kataoka T, Schröter M, Hofmann K, Irmler M, Bodmer JL, et al. APRIL, a new ligand of the TNF family, stimulates tumor cell growth. J Exp Med 1998;188:1185-1190 (Pubitemid 28443341)
3. Stadanlick JE, Cancro MP. BAFF and the plasticity of peripheral B cell tolerance. Curr Opin Immunol 2008;20:158-161
4. Mackay F, Woodcock SA, Lawton P, Ambrose C, Baetscher M, Schneider P, et al. Mice transgenic for BAFF develop lymphocytic disorders, along with autoimmune manifestations. J Exp Med 1999;190:1697-1710 (Pubitemid 30002351)
5. George-Chandy A, Trysberg E, Eriksson K. Raised intrathecal levels of APRIL and BAFF in patients with systemic lupus erythematosus: relationship to neuropsychiatric symptoms. Arthritis Res Ther 2008;10:R97.
6. Tan SM, Xu D, Roschke V, Perry JW, Arkfeld DG, Ehresmann GR, et al. Local production of B lymphocyte stimulator protein and APRIL in arthritic joints of patients with inflammatory arthritis. Arthritis Rheum 2003;48:982-992 (Pubitemid 36418240)
7. Groom J, Kalled SL, Cutler AH, Olson C, Woodcock SA, Schneider P, et al. Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjögren's syndrome. J Clin Invest 2002;109:59-68. (Pubitemid 34052542)
8. Cambridge G, Stohl W, Leandro MJ, Migone TS, Hilbert DM, Edwards JC. Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse. Arthritis Rheum 2006;54:723-732
9. Pers JO, Devauchelle V, Daridon C, Bendaoud B, Le Berre R, Bordron A, et al. BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sjögren's syndrome. Arthritis Rheum 2007;56:1464-1477 (Pubitemid 46764075)
10. Bosello S, Youinou P, Daridon C, Tolusso B, Bendaoud B, Pietrapertosa D, et al. Concentrations of BAFF correlate with autoantibody levels, clinical disease activity, and response to treatment in early RA. J Rheumatol 2008;35:1256-1264 (Pubitemid 352000768)
11. Becker-Merok A, Nikolaisen C, Nossent HC. B-lymphocyte activating factor in systemic lupus erythematosus and rheumatoid arthritis in relation to autoantibody levels, disease measures and time. Lupus 2006;15:570-576 (Pubitemid 44661743)
12. Toubi E, Kessel A, Rosner I, Rozenbaum M, Paran D, Shoenfeld Y. The reduction of serum B-lymphocyte activating levels following quinacrine add-on therapy in systemic lupus erythematosus. Scand J Immunol 2006;63:299-303.
13. Collins CE, Gavin AL, Migone TS, Hilbert DM, Nemazee D, Stohl W. B lymphocyte stimulator (BLyS) isoforms in systemic lupus erythematosus: disease activity correlates better with blood leukocyte BLyS mRNA levels than with plasma BLyS protein levels. Arthritis Res Ther 2006;8:R6.
14. Carter RH, Zhao H, Liu X, Pelletier M, Chatham W, Kimberly R, Zhou T. Expression and occupancy of BAFF-R on B cells in systemic lupus erythematosus. Arthritis Rheum 2005;52:3943-3954 (Pubitemid 41798234)
15. Gao H, Bian A, Zheng Y, Li R, Ji Q, Huang G, et al. sBAFF mutants induce neutralizing antibodies against BAFF. FEBS Lett 2007;581:581-586 (Pubitemid 46216282)
16. Bossen C, Schneider P. BAFF, APRIL and their receptors: structure, function and signaling. Semin Immunol 2006;18:263-275 (Pubitemid 44287558)
17. Gavin AL, Aït-Azzouzene D, Ware CF, Nemazee D. DeltaBAFF, an alternate splice isoform that regulates receptor binding and biopresentation of BAFF. J Biol Chem 2003;278:38220-38228
18. Pradet-Balade B, Medema JP, López-Fraga M, Lozano JC, Kolfschoten GM, Picard A, et al. An endogenous hybrid mRNA encodes TWE-PRIL, a functional cell surface TWEAK-APRIL fusion protein. EMBO J 2002;21:5711-5720 (Pubitemid 35315271)
19. Roschke V, Sosnovtseva S, Ward CD, Hong JS, Smith R, Albert V, et al. BLyS and APRIL form biologically active heterotrimers that are expressed in patients with systemic immune-based rheumatic diseases. J Immunol 2002;169:4314-4321 (Pubitemid 35178204)
20. Diao Z, Ye T, Cao P, Zhang J, Mei J, Lin Z, Zhang S. Expression, purification, and characterization of recombinant human soluble BAFF secreted from the yeast Pichia pastoris. Protein Expr Purif 2007;54:11-17 (Pubitemid 46636311)
21. Nardelli B, Belvedere O, Roschke V, Moore PA, Olsen HS, Migone TS, et al. Synthesis and release of B-lymphocyte stimulator from myeloid cells. Blood 2001;97:198-204. (Pubitemid 32061261)
22. Le Pottier L, Bendaoud B, Dueymes M, Daridon C, Youinou P, Shoenfeld Y, et al. BAFF, a new target for IVIg in autoimmunity and cancer. J Clin Immunol 2007;27:257-265
23. Zolotarjova N, Martosella J, Nicol G, Bailey J, Boyes BE, Barrett WC. Differences among techniques for high-abundant protein depletion. Proteomics 2005;5:3304-3313 (Pubitemid 41192037)
24. Patel T, Bruce J, Merry A, Bigge C, Wormald M, Jacques A, et al. Use of hydrazine to release in intact and unreduced form both N- and O-linked oligosaccharides from glycoproteins. Biochemistry 1993;32:679-693 (Pubitemid 23034909)
25. Basset C, Durand V, Mimassi N, Pennec YL, Youinou P, Dueymes M. Enhanced sialyltransferase activity in B lymphocytes from patients with primary Sjögren's syndrome. Scand J Immunol 2000;51:307-311 (Pubitemid 30151515)
26. Mariette X, Roux S, Zhang J, Bengoufa D, Lavie F, Zhou T, et al. The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjögren's syndrome. Ann Rheum Dis 2003;62:168-171 (Pubitemid 36135394)
27. A committee of the American Rheumatism Association. 1958 revision of diagnostic criteria for rheumatoid arthritis: by a committee of the American Rheumatism Association. Arthritis Rheum 2008;58(2 Suppl):S15-9.
28. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.
29. Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, et al. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002;61:554-558 (Pubitemid 34539104)
30. Zhang J, Roschke V, Baker KP, Wang Z, Alarcón GS, Fessler BJ, et al. Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus. J Immunol 2001;166:6-10. (Pubitemid 32038409)
31. Joshi KS, Hoffmann LG, Butler JE. The immunochemistry of sandwich ELISAs - V. the capture antibody performance of polyclonal antibody-enriched fractions prepared by various methods. Mol Immunol 1992;29:971-981
32. Pers JO, Daridon C, Devauchelle V, Jousse S, Saraux A, Jamin C, Youinou P. BAFF overexpression is associated with autoantibody production in autoimmune diseases. Ann N Y Acad Sci 2005;1050:34-39 (Pubitemid 41129420)
33. Pers JO, d'Arbonneau F, Devauchelle-Pensec V, Saraux A, Pennec YL, Youinou P. Is periodontal disease mediated by salivary BAFF in Sjögren's syndrome? Arthritis Rheum 2005;52:2411-2414
34. Cao P, Mei JJ, Diao ZY, Zhang S. Expression, refolding, and characterization of human soluble BAFF synthesized in Escherichia coli. Protein Expr Purif 2005;41:199-206. (Pubitemid 40406380)
35. Stohl W. Systemic lupus erythematosus: a blissless disease of too much BLyS (B lymphocyte stimulator) protein. Curr Opin Rheumatol 2002;14:522-528 (Pubitemid 34953788)
36. Gavin AL, Duong B, Skog P, Aït-Azzouzene D, Greaves DR, Scott ML, Nemazee D. DeltaBAFF, a splice isoform of BAFF, opposes full-length BAFF activity in vivo in transgenic mouse models. J Immunol 2005;175:319-328 (Pubitemid 40884334)
37. Hashii N, Kawasaki N, Itoh S, Nakajima Y, Kawanishi T, Yamaguchi T. Alteration of N-glycosylation in the kidney in a mouse model of systemic lupus erythematosus: relative quantification of N-glycans using an isotope-tagging method. Immunology 2008;126:336-345
38. Furie R, Stohl W, Ginzler EM, Becker M, Mishra N, Chatham W, et al. Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus. Arthritis Res Ther 2008;10:R109.
39. Youinou P. Is BAFF the murderer in lupus? Lupus 2008;17:613-614